CCCC
NASDAQ
US
C4 Therapeutics, Inc. - Common Stock
$2.82
▲ +$0.12
(+4.44%)
Vol 2.1M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$185.1M
ROE
-64.4%
Margin
-395.5%
D/E
0.00
Beta
2.93
52W
$1–$4
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
FHTX
Foghorn Therapeutics Inc
$305.4M
ORGO
Organogenesis Holdings Inc
P/E 654.1
$657.4M
NBP
NovaBridge Biosciences
$458.9M
AVXL
Anavex Life Sciences Corp
$318.1M
TARA
Protara Therapeutics Inc
$275.2M
ABEO
Abeona Therapeutics Inc
P/E 3.5
$285.6M
ALEC
Alector Inc
$170.3M
EDIT
Editas Medicine Inc
$200.1M
TLSI
TriSalus Life Sciences Inc
$348.8M
About C4 Therapeutics, Inc. - Common Stock
На жаль, інформація про компанію CCCC в галузі Biotechnology відсутня у відкритих джерелах. Щоб надати релевантний опис, потрібні додаткові дані про її діяльність, ринкову позицію та конкурентні переваги. Без цієї інформації неможливо зробити обґрунтований аналіз.
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.31 | $-0.18 | +$0.13 |
| Sep 2025 | $-0.41 | $-0.44 | $-0.03 |
| Jun 2025 | $-0.39 | $-0.37 | +$0.02 |
| Mar 2025 | $-0.46 | $-0.37 | +$0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $5.2M | $7.2M | $6.5M | $11.2M | $11.0M |
| Net Income | — | -$34.6M | -$26.3M | -$26.0M | -$32.2M | -$20.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -53.9% | -53.9% | -53.9% | -53.9% | -64.4% | -64.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -402.6% | -325.9% | -325.9% | -325.9% | -395.5% | -395.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.06 | 5.06 | 5.06 | 5.06 | 5.75 | 5.75 |
Key Ratios
ROA (TTM)
-38.7%
P/S (TTM)
6.15
P/B
1.2
EPS (TTM)
$-1.67
CF/Share
$-2.71
Rev Growth 3Y
-8.1%
52W High
$4.26
52W Low
$1.09
$1.09
52-Week Range
$4.26
Financial Health
Free Cash Flow
-$22.2M
Net Debt
-$14.6M
Cash
$74.6M
Total Debt
$60.0M
As of Dec 31, 2025
How does CCCC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CCCC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
6.2
▼
52%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.2
▼
52%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CCCC profitability vs Biotechnology peers
ROE
-64.4%
▲
4%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-395.5%
▼
38%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-38.7%
▲
17%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CCCC financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.8
▲
30%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.9
▲
202%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CCCC fundamentals radar
CCCC
Peer median
Industry
CCCC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CCCC vs peers: key metrics
Latest News
No related news yet